Ocular Complications of Intravitreal Avastin: a Report from Tobruk Medical Center

• Fathy A. Abdolmejed

  Ophthalmology department, Faculty of medicine, Tobruck, Libya

  Author

• Ghamela S. Ali

  Pediatric Department, Tobruk University, Tobruk, Libya

  Author

A retrospective statistical study was done at the ophthalmology department of Tobruk Medical Center on all the patients who received intravitreal medication with Avastin (anti-VEGF (anti-vascular endothelial growth factor)) in the period between August 1^st and December 31^st, 2018. It is aimed to report the complications of the intravitreal injection (IVI) and how they were managed. Out of the 56 recorded patients, there were 32 (51.9 %) females, all the patients received multiple intravitreal injections, with a total number of 131 injections. The average age of the patients was 56.5 years (ranged from 40-70 years). The most common complications after intravitreal injection were subconjunctival hemorrhage (19%), discomfort/pain (13.7%), blurring of vision (6 %), leaking at injection site (4.6%), floaters (3%), and increase intraocular pressure (IOP) in (13.7%). Six cases out of the eighteen that had high IOP received Diamox (Acetazolamide) Tab. 250 mg one-two hours before the time of injection which did not prevent the post-injection spike of IOP and that was statistically not significant (P=0.09). Thirteen eyes (10 %) developed sudden loss of vision due to sudden increase in IOP immediately after the injection, and all the cases of the high IOP were managed by anterior chamber paracentesis and the vision also improved. Endophthalmitis was recorded in only one case (0.8%), at the third-day post intraocular Avastin injection, the causative microorganism was unknown and treated with intravitreal antibiotics (vancomycin) along with topical and systemic antibiotics and steroids, but the patient did not recover until pars plana vitrectomy was done to him, and the patient recovered his preoperative vision. The patients who had glaucoma or rubeosis iridis suffered significantly (P = 0.01) from an increase in IOP levels (digitally measured) after injection with Avastin, while most other patients who didn't have both pathologies did not suffer from an increase in IOP. Concluded that despite Anti-VEGF has a dramatic effect on the quality of life by improving the central vision, it can cause serious complications that could be prevented by early diagnosis and treatment.    

Aiello, L. P., Brucker, A. J., Chang, S., Cun-ningham, E. T., Jr, D'Amico, D. J., Flynn, H. W., Jr, Grillone, L. R., Hutcherson, S., Liebmann, J. M., O'Bri-en, T. P., Scott, I. U., Spaide, R. F., Ta, C., & Trese, M. T. (2004). Evolving guidelines for intravitreous injec-tions. Retina (Philadelphia, Pa.), 24(5 Suppl), S3–S19. https://doi.org/10.1097/00006982-200410001-00002

Barry P, Cordovés L, Gardner S.(2013). ESCRS Guidelines for Pre-vention and Treatment of Endophthal-mitis following Cataract Surgery: Data, Dilemmas and Conclusions. Paper Pre-sented at the European Society of Cata-ract and Refractive Surgeons. Dublin, Ireland: 2013.https://www.escrs.org/downloads/Endophthalmitis-Guidelines.pdf. Ac-cessed July 25, 2020

Bertino J. S., Jr (2009). Impact of antibiotic re-sistance in the management of ocular in-fections: the role of current and future

antibiotics. Clinical ophthalmology (Auckland, N.Z.), 3, 507–521. https://doi.org/10.2147/opth.s5778

Callegan, M. C., Engelbert, M., Parke, D. W., 2nd, Jett, B. D., & Gilmore, M. S. (2002). Bacterial endophthalmitis: epi-demiology, therapeutics, and bacterium-host interactions. Clinical microbiology reviews, 15(1), 111–124. https://doi.org/10.1128/cmr.15.1.111-124.2002

Damasceno, N. P., Horowitz, S. A., & Damasceno, E. F. (2016). Leuconostoc as a Cause of Endophthalmitis Post-intravitreal Injection of Ranibi-zumab. Ocular immunology and in-flammation, 24(1), 118–119. https://doi.org/10.3109/09273948.2014.898073.

Dancer, S. J., Stewart, M., Coulombe, C., Gre-gori, A., & Virdi, M. (2012). Surgical site infections linked to contaminated surgical instruments. The Journal of hospital infection, 81(4), 231–238. https://doi.org/10.1016/j.jhin. 2012.04.023

Dhoot SB, Kunjukunju N, Sabates N. (2013).The role of prophylactic antibi-otic use in prevention of endophthalmi-tis following intravitreal injection of an-ti-vascular endothelial growth factor agents: a meta-analysis. Open J Oph-thalmol., 3(2):46–49.

Fang, Y. T., Chien, L. N., Ng, Y. Y., Chu, H. F., Chen, W. M., Cheng, C. Y., & Wu, S. C. (2006). Association of hospital and surgeon operation volume with the incidence of postoperative endophthal-mitis: Taiwan experience. Eye (London, England) , 20(8), 900–907. https://doi.org/-10.1038/sj. eye.6702045

Frenkel, M.P., Haji, S.A. and Frenkel, R.E. (2010) Effect of Prophylactic Intraocu-lar Pressure-Lowering Medication on Intraocular Pressure Spikes after Intravi-treal Injections. Arch Ophthalmol, 128, 1523-1527. http://dx.doi.org/10.1001/archophthalmol.2010.297

Hoevenaars, N. E., Gans, D., Missotten, T., van Rooij, J., Lesaffre, E., & van Meurs, J. C. (2012). Suspected bacterial endoph-thalmitis following intravitreal anti-VEGF injection: case series and litera-ture review. Ophthalmologica. Journal international d'ophtalmologie. Interna-tional journal of ophthalmology. Zeitschrift fur Augenheilkunde, 228(3), 143–147. https://doi.org/10.1159/000339584

Hoguet, A., Chen, P. P., Junk, A. K., Mruthyunjaya, P., Nouri-Mahdavi, K., Radhakrishnan, S., Takusagawa, H. L., & Chen, T. C. (2019). The Effect of Anti-Vascular Endothelial Growth Fac-tor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmolo-gy. Ophthalmology, 126(4), 611–622.

Hollands, H., Wong, J., Bruen, R., Campbell, R. J., Sharma, S., & Gale, J. (2007). Short-term intraocular pressure changes after intravitreal injection of bevaci-zumab. Canadian journal of ophthal-mology. Journal canadien d'ophtalmol-ogie, 42(6), 807–811. https://doi.org/10.3129/i07-172

Oztas, Z., Akkin, C., Afrashi, F., & Nalcaci, S. (2016). The short-needle intravitreal in-jection technique. International journal of ophthalmology, 9(6), 929–930. https://doi.org/10.18240/ijo.2016.06.24

Park, J. C., Ramasamy, B., Shaw, S., Prasad, S., & Ling, R. H. (2014). A prospective and nationwide study investigating en-dophthalmitis following pars plana vitrectomy: incidence and risk fac-tors. The British journal of ophthalmol-ogy, 98(4), 529–533. https://doi.org/10.1136/bjophthalmol-2013-304485

Pulido, J. S., Pulido, C. M., Bakri, S. J., McCannel, C. A., & Cameron, J. D. (2007). The use of 31-gauge needles and syringes for intraocular injec-tions. Eye (London, England), 21(6), 829–830. https://doi.org/10.1038/sj.eye.6702514

Qureshi, N. A., Mansoor, H., Ahmad, S., Zafar, S., & Asif, M. (2016). Reducing intra-ocular-pressure spike after intravitreal-bevacizumab injection with ocular de-compression using a sterile cotton swab soaked in proparacaine 0.5%: A quasi-experimental study. Taiwan journal of ophthalmology, 6(2), 75–78. https:/ /doi.org/10.1016/j.tjo.2015.12.003

Sachdeva, M. M., Moshiri, A., Leder, H. A., & Scott, A. W. (2016). Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. Journal of ophthalmic in-flammation and infection, 6(1), 2. https://doi.org/10.1186/s12348-015-0069-5

Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., & Costagliola, C. (2015). Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal In-jection. Current drug metabolism, 16(7), 572–584. https://doi.org/10.2174/1389200216666151001120831

Shah, Chirag P; Garg, Sunir J; Vander, James F; Brown, Gary C; Kaiser, Richard S; Haller, Julia A; and The Post-Injection Endophthalmitis (PIE) Study Team (2011). "Outcomes and risk factors as-sociated with endophthalmitis after in-travitreal injection of anti-vascular en-dothelial growth factor agents." Oph-thalmology, 118 (10): 2028-2034.

Solborg Bjerrum, S., Kiilgaard, J. F., Mikkel-sen, K. L., & la Cour, M. (2013). Out-sourced cataract surgery and postopera-tive endophthalmitis. Acta ophthalmo-logica, 91(8), 701–708. https://doi.org/10.1111/aos.12279

Song, S., Yu, X. B., & Dai, H. (2016). Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study. Indian journal of ophthalmolo-gy, 64(10), 762–766. https://doi.org/10.4103/0301-4738.195006

Tufan, H.A., Vural, A.H., Gencer, B., Kara, S., Arıkan, S., & Yuksel, E. (2013). Bacte-rial Contamination of Needles Used for Intravitreal Injections: Comparison be-tween 27-gauge and 30-gauge Nee-dles. Ocular Immunology and Inflam-mation, 21, 366 – 370, DOI: 10.3109/09273948.2013.801988

Uyar, E., Ulas, F., Sahin, S., & Celebi, S. (2019). Major factors affecting intraocu-lar pressure spike after intravitreal ranibizumab injection: Vitreous reflux and its amount. European Journal of Ophthalmology, 29(4), 361–367. https://doi.org/10.1177/1120672119836613

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright of the articles Published by Almukhtar Journal of Science (MJSc) is retained by the author(s), who grant MJSc a license to publish the article. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors and cite MJSc as the original publisher. Also, they accept the article remains published by the MJSc website (except in the occasion of a retraction of the article).